Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

8a537b1e-3937-467b-b258-8ed4ddae6550 - samples

ABSTRACT: RRBS data from TRACERx non-small cell lung cancer (NSCLC) tumours and matched normal adjacent tissue. TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC).

PROVIDER: EGAD00001009707 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

TRACERx NSCLC - Whole exome multiregion sequencing data

| EGAS00001006494 | EGA

Multi-region RNA sequencing of tumour regions and tumour-adjacent normal lung tissue

| EGAS00001006517 | EGA

RRBS data from TRACERx non-small cell lung cancer (NSCLC) tumours and matched normal adjacent tissue.

| EGAS00001006523 | EGA

TRACERx 100: RNAseq data from the first 100 TRACERx tumours

| EGAS00001003458 | EGA

TRACERx 100: RRBS data from a subset of the first 100 TRACERx tumours

Project description:TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC). This study looks at multi-region RRBS data from the TRACERx100 cohort selected for quantity of material available and high tumour purity. RRBS data was collected for 122 tumour regions across 36 patients each with matched normal. A subset of this cohort was used in a sister study looking at tumour neo-antigen promoter methylation status in NSCLC (71 tumour regions across 28 patients for a total of 99 samples).

| EGAS00001003484 | EGA

Homo sapiens

Project description:Intratumor heterogeneity of gene expression profiles in early stage non-small cell lung cancer (NSCLC)

| PRJNA148907 | ENA

ena-DATASET-CRICK-07-03-2017-14:09:10:769-11 - samples

Project description:BACKGROUND TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC). METHODS Multiregion high-depth whole-exome sequencing (M-seq) was performed on 100 early stage NSCLC tumors resected prior to systemic therapy. A total of 327 tumor regions were sequenced and analyzed to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between ITH and recurrence-free survival (RFS). RESULTS Widespread ITH was observed for both somatic copy number alterations (median 48% [0.03-88%]) and mutations (median 30% [0.5-93%]). Driver mutations in EGFR, MET, BRAF and TP53 were almost always clonal. However, heterogeneous driver alterations occurring later in evolution were found in over 75% of tumors and were common in PIK3CA, NF1 and genes involved in chromatin modification and DNA response and repair. Genome doubling and ongoing dynamic chromosomal instability (CIN), illustrated by mirrored subclonal allelic imbalance, were identified as causes of ITH resulting in parallel evolution of driver copy number events, including amplifications of CDK4, FOXA1, and BCL11A. Elevated copy number heterogeneity was associated with shorter RFS (HR=4.9, P=0.00044), which remained significant in a multivariate analysis. CONCLUSIONS ITH mediated through CIN, rather than point mutational heterogeneity, was associated with increased risk of relapse, supporting its value as a prognostic predictor, and the need to target this high-risk phenotype.

| EGAD00001003206 | EGA

Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

Project description:Lung cancer remains the leading cause of mortality from malignant tumors, non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases, and individualized diagnosis and treatment in traditional Chinese Medicine (TCM) is an effective trend. In this study, a proteomics research with DIA mode and a non-targeted lipidomics research were developed in NSCLC patients with Qi deficiency and Yin deficiency (QDYD) and Qi deficiency of lung-spleen (QDLS) syndromes.

2021-09-24 | PXD024704 | iProX

Gene expression analysis of lung cancer samples and healthy controls

Project description:Non-small cell lung cancer (NSCLC, n=22) and normal adjacent control biopsies (n=18) from patients with lung cancer were obtained for Affymetrix GeneChip analysis. NSCLC samples were grouped into squamous cell carcinoma (SCC, n=11) and adenocarcinoma (AC, n=11) samples.

2017-07-01 | E-MTAB-5231 | biostudies-arrayexpress

Re-expression of SMARCA4/BRG1 in Small Cell Carcinoma of Ovary, Hypercalcemic Type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism [A427_RNA-seq]

Project description:A427 (NSCLC - Non-Small Cell Lung Cancer) cells +/- BRG1 re-expression - RNA-seq

2021-01-01 | GSE164131 | GEO